1
|
Patel P, Schrader KE, Rice CE, Rowley E, Cree RA, DeSilva MB, Embi PJ, Gaglani M, Grannis SJ, Ong TC, Stenehjem E, Naleway AL, Ball S, Natarajan K, Klein NP, Adams K, Kharbanda A, Ray C, Link-Gelles R, Tenforde MW. Effectiveness of the Original Monovalent Coronavirus Disease 2019 Vaccines in Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Adults With Disabilities: VISION Network, June 2021-September 2022. Open Forum Infect Dis 2023; 10:ofad474. [PMID: 37965644 PMCID: PMC10642729 DOI: 10.1093/ofid/ofad474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Accepted: 09/18/2023] [Indexed: 11/16/2023] Open
Abstract
Adults with disabilities are at increased risk for severe coronavirus disease 2019 (COVID-19). Using data across 9 states during Delta- and Omicron-predominant periods (June 2021-September 2022), we evaluated the effectiveness of the original monovalent COVID-19 messenger RNA vaccines among 521 206 emergency department/urgent care encounters (11 471 [2%] in patients with a documented disability) and 139 548 hospitalizations (16 569 [12%] in patients with a disability) for laboratory-confirmed COVID-19 illness in adults (aged ≥18 years). Across variant periods and for the primary series or booster doses, vaccine effectiveness was similar in those with and those without a disability. These findings highlight the importance of adults with disabilities staying up to date with COVID-19 vaccinations.
Collapse
Affiliation(s)
- Palak Patel
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | - Catherine E Rice
- Division of Human Development and Disability, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Elizabeth Rowley
- Department of Clinical Research, Westat, Rockville, Maryland, USA
| | - Robyn A Cree
- Division of Human Development and Disability, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Malini B DeSilva
- Department of Research, Health Partners Institute, Minneapolis, Minnesota, USA
| | - Peter J Embi
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Manjusha Gaglani
- Section of Pediatric Infectious Diseases, Department of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA
- Department of Medical Education, Texas A&M University College of Medicine, Temple, Texas, USA
| | - Shaun J Grannis
- Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA
- School of Medicine, Indiana University, Indianapolis, Indiana, USA
| | - Toan C Ong
- School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Edward Stenehjem
- Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA
| | - Allison L Naleway
- Department of Science Programs, Kaiser Permanente Center for Health Research, Portland, Oregon, USA
| | - Sarah Ball
- Department of Clinical Research, Westat, Rockville, Maryland, USA
| | - Karthik Natarajan
- Department of Biomedical Informatics, Columbia University Irving Medical Center, NewYork, New York, USA
- Medical Informatics Services, NewYork-Presbyterian Hospital, NewYork, New York, USA
| | - Nicola P Klein
- Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA
| | - Katherine Adams
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Anupam Kharbanda
- Department of Emergency Medicine, Children’s Minnesota, Minneapolis, Minnesota, USA
| | - Caitlin Ray
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Ruth Link-Gelles
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Mark W Tenforde
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
2
|
Meslin EM, Rager JB, Schwartz PH, Quaid KA, Gaffney MM, Duke J, Tierney WH. Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest. Clin Transl Med 2015; 4:36. [PMID: 26668063 PMCID: PMC4678144 DOI: 10.1186/s40169-015-0077-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 11/29/2015] [Indexed: 11/30/2022] Open
Abstract
Relationships between industry and university-based researchers have been commonplace for decades and have received notable attention concerning the conflicts of interest these relationships may harbor. While new efforts are being made to update conflict of interest policies and make industry relationships with academia more transparent, the development of broader institutional partnerships between industry and academic health centers challenges the efficacy of current policy to effectively manage these innovative partnerships. In this paper, we argue that existing strategies to reduce conflicts of interest are not sufficient to address the emerging models of industry-academic partnerships because they focus too narrowly on financial matters and are not comprehensive enough to mitigate all ethical risk. Moreover, conflict-of-interest strategies are not designed to promote best practices nor the scientific and social benefits of academic-industry collaboration. We propose a framework of principles and benchmarks for "ethically credible partnerships" between industry and academic health centers and describe how this framework may provide a practical and comprehensive approach for designing and evaluating such partnerships.
Collapse
Affiliation(s)
- Eric M Meslin
- Indiana University Center for Bioethics, 410 West 10th Street, Indianapolis, IN, 46202, USA.
| | - Joshua B Rager
- Indiana University Center for Bioethics, 410 West 10th Street, Indianapolis, IN, 46202, USA.
| | - Peter H Schwartz
- Indiana University Center for Bioethics, 410 West 10th Street, Indianapolis, IN, 46202, USA.
| | - Kimberly A Quaid
- Indiana University Center for Bioethics, 410 West 10th Street, Indianapolis, IN, 46202, USA.
| | - Margaret M Gaffney
- Indiana University Center for Bioethics, 410 West 10th Street, Indianapolis, IN, 46202, USA.
| | - Jon Duke
- Regenstrief Institute Inc., 410 West 10th Street, Indianapolis, IN, 46202, USA.
| | - William H Tierney
- Regenstrief Institute Inc., 410 West 10th Street, Indianapolis, IN, 46202, USA.
| |
Collapse
|